Side-by-side comparison of AI visibility scores, market position, and capabilities
San Ramon CA contact lenses and fertility devices (NASDAQ: COO) $3.87B FY2024 revenue (+9%); CooperVision MiSight myopia management, CooperSurgical IVF consumables, competing with J&J Vision and Alcon.
The Cooper Companies, Inc. is a San Ramon, California-based medical device company — publicly traded on the NASDAQ (NASDAQ: COO) as an S&P 500 Health Care component — operating two segments: CooperVision (soft contact lenses for vision correction globally — the second-largest contact lens manufacturer worldwide) and CooperSurgical (fertility and women's health medical devices including IVF laboratory consumables, assisted reproductive technology products, and gynecological surgical instruments) through approximately 15,000 employees in 130 countries. In fiscal year 2024 (ending October 2024), Cooper Companies reported revenues of $3.87 billion (+9% organic growth), with CooperVision generating $2.56 billion from daily, biweekly, and monthly contact lens sales across sphere, toric (astigmatism-correcting), and multifocal (presbyopia-correcting) lens categories, and CooperSurgical generating $1.31 billion from fertility clinic consumables and women's health surgical products. CEO Albert White has executed CooperVision's strategy of capturing the premium daily silicone hydrogel lens market: silicone hydrogel material (higher oxygen permeability improving eye health versus conventional hydrogel) commands a 20-30% price premium over conventional daily lenses, and Cooper's MyDay (premium daily silicone hydrogel) and clariti (value silicone hydrogel) brands compete across price tiers against Johnson & Johnson Vision's Acuvue Oasys and CIBA Vision's AIR OPTIX brands for the global market shift toward dailies — the fastest-growing contact lens modality as patients prefer the convenience and hygiene of discarding lenses after each day's wear.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.